ARTV
Artiva Biotherapeutics, Inc.
Latest Form 4:Sale$99KbyBanerjee Subhashis (Chief Medical Officer) · filed Aug 31, 2026
Artiva Biotherapeutics, Inc. (ARTV) has 36 SEC Form 4 filings (54 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 31, 2026.
The most active filer is Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. with 19 filings. Insiders have net bought $108.6M over the trailing 6 months. The largest single insider purchase in this window was $75.0M by Director, 10% Owner RA CAPITAL MANAGEMENT, L.P. on May 11, 2026.
- Industry:Biotechnology
- CEO:Fred Aslan
- Employees:96
- HQ:San Diego, CA, US
- IPO:2024-07-19
Insider Buying
$109.2M
reported purchases (SEC code P)
Insider Selling
$775K
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$552.5M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Medical Officer | Sale | 8,222 | $99K | Aug 31 | SEC ↗ | |
Banerjee SubhashisFirst in 3 months | Chief Medical Officer | Sale | 429 | $5K | Aug 20 | SEC ↗ |
| Director, 10% Owner | Purchase | 20,824 | $208K | Jul 31 | SEC ↗ | |
| Director, 10% Owner | Purchase | 24,944 | $248K | Jul 31 | SEC ↗ | |
| Director, 10% Owner | Purchase | 41,319 | $413K | Jul 28 | SEC ↗ | |
| Director, 10% Owner | Purchase | 120,582 | $1.2M | Jul 24 | SEC ↗ | |
| Director, 10% Owner | Purchase | 84,124 | $835K | Jul 24 | SEC ↗ | |
| Director, 10% Owner | Purchase | 59,880 | $596K | Jul 24 | SEC ↗ | |
| Director, 10% Owner | Purchase | 13,074 | $117K | Jul 24 | SEC ↗ | |
| Director, 10% Owner | Purchase | 152,472 | $1.4M | Jul 20 | SEC ↗ | |
| Director, 10% Owner | Purchase | 7,882 | $71K | Jul 20 | SEC ↗ | |
| Director, 10% Owner | Purchase | 15,102 | $135K | Jul 14 | SEC ↗ | |
| Director, 10% Owner | Purchase | 31,000 | $275K | Jun 29 | SEC ↗ | |
| Director, 10% Owner | Purchase | 1,876 | $17K | Jun 29 | SEC ↗ | |
| Director, 10% Owner | Purchase | 391,019 | $3.4M | Jun 16 | SEC ↗ | |
| Director, 10% Owner | Purchase | 15,414 | $139K | Jun 16 | SEC ↗ | |
| Director, 10% Owner | Purchase | 124,893 | $1.1M | Jun 16 | SEC ↗ | |
| Director, 10% Owner | Purchase | 479,039 | $3.3M | Jun 11 | SEC ↗ | |
| Director, 10% Owner | Purchase | 103 | $721 | Jun 11 | SEC ↗ | |
| Director, 10% Owner | Purchase | 548,580 | $4.3M | Jun 11 | SEC ↗ | |
GC Corp.First filing | 10% Owner | Purchase | 1,432,291 | $16.5M | May 28 | SEC ↗ |
Raymon HeatherFirst filing | SVP, Research and Development | Sale | 3,095 | $28K | May 20 | SEC ↗ |
Horan ChristopherFirst filing | Chief Tech Operations Officer | Sale | 7,002 | $63K | May 20 | SEC ↗ |
Bush JenniferFirst filing | COO, CLO, Compliance Officer | Sale | 8,790 | $79K | May 20 | SEC ↗ |
Banerjee SubhashisFirst filing | Chief Medical Officer | Sale | 7,037 | $63K | May 20 | SEC ↗ |
Aslan FredFirst in 5 months | Chief Executive Officer | Sale | 27,116 | $244K | May 20 | SEC ↗ |
| Director, 10% Owner | Purchase | 6,510,416 | $75.0M | May 13 | SEC ↗ | |
| President and CEO | Sale | 3,187 | $19K | Dec 15 | SEC ↗ | |
| President and CEO | Sale | 6,375 | $22K | Nov 17 | SEC ↗ | |
Aslan FredFirst filing | President and CEO | Sale | 25,500 | $153K | Oct 17 | SEC ↗ |
Related companies
Artiva Biotherapeutics, Inc. is in the Healthcare sector.